Clinical Trial Update: Raloxifene and Rimostil for Perimenopause-Related Depression [Phase 4]

View source ↗

Summary

Phase 4 study by the National Institute of Mental Health evaluating raloxifene (Rimostil) for perimenopause-related depression and depression has completed. Res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Raloxifene (raloxifene)
• Rimostil (raloxifene)

Snippet

Sponsor: National Institute of Mental Health (NIMH) | Conditions: Perimenopausal Depression, Depression | Phase 4 | Status: COMPLETED | Results posted: 2016-09-05